MLTX · CIK 0001821586
MOONLAKE IMMUNOTHERAPEUTICS
Annual figures as reported, FY2020–FY2025. Ratios and growth rates derived on-page.
Pharmaceutical Preparations
Company profile
Net income
−$227.3M
▼ −91.1% vs FY2024
Free cash flow
−$196.0M
▼ −67.4% vs FY2024
Diluted EPS
−$3.53
▼ −86.8% vs FY2024
Net income
Losses shown in terracotta
Recent quarters
momentum · last 12 quartersNet income — Mar ’26 quarter
−$69.7M
▼ −74.5% vs Mar ’25
Diluted EPS — trailing 12 months
−$3.88
▼ −68.7% vs Mar ’25
Quarterly net income
Losses shown in terracotta
| Quarter | Revenue | Rev. YoY | Gross margin | Net income | Net margin | Diluted EPS |
|---|---|---|---|---|---|---|
| Mar ’26 | — | — | — | −$69.7M | — | −$0.98 |
| Dec ’25 | — | — | — | −$62.4M | — | −$0.93 |
| Sep ’25 | — | — | — | −$69.7M | — | −$1.10 |
| Jun ’25 | — | — | — | −$55.2M | — | −$0.87 |
| Mar ’25 | — | — | — | −$39.9M | — | −$0.63 |
| Dec ’24 | — | — | — | −$45.6M | — | −$0.72 |
| Sep ’24 | — | — | — | −$35.4M | — | −$0.56 |
| Jun ’24 | — | — | — | −$24.3M | — | −$0.39 |
Profitability & returns
quality of earningsReturns on capital
Net income vs year-end equity and assets
Return on equityReturn on assets
Cash flow
cash generationFree cash flow
Operating cash flow less capital expenditure
Operating cash flow
Net cash from operations
Shareholder returns
capital allocationCapital returned
Cash paid out as dividends and share repurchases
Buybacks
Diluted shares outstanding
Falling count means buybacks outpace dilution
Balance sheet
financial positionStockholders’ equity
At fiscal year end
Net debt
Long-term debt less cash — negative means net cash
Key ratios
derived per fiscal year| Fiscal year | ROE | ROA | Current ratio | Debt / equity |
|---|---|---|---|---|
| FY2025 | −74.7% | −53.6% | 9.27× | 0.24× |
| FY2024 | −26.6% | −24.9% | 21.11× | 0.00× |
| FY2023 | −7.3% | −6.8% | 51.59× | — |
| FY2022 | −102.2% | −65.0% | 9.98× | — |
| FY2021 | — | −46.9% | 0.46× | — |
| FY2020 | — | — | 12.93× | — |
Annual figures
as reported| Fiscal year | Revenue | Gross profit | Op. income | Net income | Diluted EPS | Op. cash flow | Capex | Total assets | Liabilities | Equity | Cash | LT debt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 | — | — | −$244.8M | −$227.3M | −$3.53 | −$196.0M | $35K | $424.4M | $120.0M | $304.5M | $334.5M | $74.1M |
| FY2024 | — | — | −$143.1M | −$118.9M | −$1.89 | −$116.6M | $520K | $477.9M | $24.5M | $446.8M | $180.4M | $0 |
| FY2023 | — | — | −$54.1M | −$36.0M | −$0.73 | −$42.8M | $284K | $526.5M | $13.0M | $495.7M | $451.2M | — |
| FY2022 | — | — | −$65.1M | −$50.0M | −$1.70 | −$55.9M | $16K | $76.8M | $8.1M | $48.9M | $39.5M | — |
| FY2021 | — | — | −$4.6M | −$4.5M | −$0.31 | −$611K | — | $9.7M | $21.3M | −$11.6M | $8.0M | — |
| FY2020 | — | — | — | — | — | — | — | $116.6M | $4.2M | −$2.5M | $1.3M | — |
Latest filings
the most recent regulatory filings4Insider ownership filing2026-07-02 ↗144Notice of proposed insider sale2026-06-30 ↗SCHEDULE 13D/ASEC filing2026-06-29 ↗8-KCURRENT REPORT2026-06-25 ↗424B5PROSPECTUS SUPPLEMENT2026-06-24 ↗4Insider ownership filing2026-06-23 ↗424B5PRELIMINARY PROSPECTUS SUPPLEMENT2026-06-22 ↗8-KCURRENT REPORT2026-06-22 ↗4OWNERSHIP DOCUMENT2026-06-22 ↗4Insider ownership filing2026-06-18 ↗
Company logos by Elbstream and unavatar.
All third-party trademarks, service marks, logos, and brand names used on this site are the property of their respective owners. The use of these logos is for identification and illustrative purposes only and does not imply any affiliation, sponsorship, or endorsement by the respective owners.